Does lack of exposure to individual antidepressants at different points during pregnancy associate with reduced risk of adverse newborn outcomes?

Margaret A Tharp; Rebecca M Silvola; Claire Marks; Evgennia Teal; Sara K Quinney; David M Haas

doi:10.1186/s12884-022-05287-6

Does lack of exposure to individual antidepressants at different points during pregnancy associate with reduced risk of adverse newborn outcomes?

BMC Pregnancy Childbirth. 2022 Dec 9;22(1):926. doi: 10.1186/s12884-022-05287-6.

Authors

Margaret A Tharp¹, Rebecca M Silvola², Claire Marks¹, Evgennia Teal³, Sara K Quinney^{1

2}, David M Haas^{4

5}

Affiliations

¹ Department of Obstetrics and Gynecology, Indiana University School of Medicine, 550 N. University Blvd, UH 2440, Indianapolis, IN, 46033, USA.
² Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA.
³ Regenstrief Institute, Indianapolis, IN, USA.
⁴ Department of Obstetrics and Gynecology, Indiana University School of Medicine, 550 N. University Blvd, UH 2440, Indianapolis, IN, 46033, USA. dahaas@iu.edu.
⁵ Department of Medicine, Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA. dahaas@iu.edu.

Abstract

Background: The objective of this study was to determine if the lack of exposure to individual antidepressants at certain times in pregnancy improved maternal and infant outcomes.

Methods: This was a retrospective cohort study of 2741 pregnant women prescribed antidepressant(s) before or during pregnancy. Data were obtained from electronic medical records. Analysis was limited to women prescribed one of five antidepressants (bupropion, citalopram, escitalopram, fluoxetine, sertraline). Period of exposure was determined using prescription order dates. Primary outcomes were neonatal intensive care unit (NICU) admission and adaptation syndrome in the newborn. Logistic regression, adjusted for maternal age, race, and insurance, compared consistent exposure throughout pregnancy versus (A) no exposure in the third trimester, (B) no exposure early in pregnancy, and (C) exposure in the midtrimester alone.

Results: Compared to women prescribed an antidepressant continually throughout pregnancy, NICU admission was less likely for women lacking exposure in the third trimester if they had been taking bupropion (aOR 0.43, 95% CI 0.21-0.90) or escitalopram (aOR 0.49, 95% CI 0.28-0.85). Women previously taking escitalopram but lacking third trimester exposure also had lower odds of adaptation syndrome (aOR 0.19, 95% CI 0.07-0.48). No differences were found in other outcomes for women taking other antidepressants or for any outcomes for women who lacked early pregnancy drug exposure compared to exposure throughout pregnancy.

Conclusion: For the five antidepressants included in this study, lack of exposure early or late in pregnancy compared to consistent exposure throughout pregnancy generally did not change newborn outcomes. The exceptions were bupropion and escitalopram, where lack of exposure in the third trimester associated with lower rates of adaptation syndrome or NICU admission. These data may help pregnant women with depression in need of drug therapy to have informed discussions with providers about the potential risks and benefits to continuing or stopping drugs at different times during pregnancy.

Keywords: Adaptation syndrome; Antidepressants; Newborn intensive care unit admission; Pregnancy; Trimester.

MeSH terms

Family*
Female
Humans
Infant, Newborn
Pregnancy
Retrospective Studies

Grants and funding

T32GM842528/GM/NIGMS NIH HHS/United States